Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease.

Drugs · 2022 · PMC9287529 · PMID 35841520

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

A 12-week, Phase 3, DBRCT involving patients with OFF episodes despite stable anti-PD treatment evaluated sublingual apomorphine (dose range of 10–30 mg) and reported significantly greater self-rated full ON response within 30 min versus placebo, corroborated by a nominally significant full ON response using home-dosing diaries.

also in 7,732 other papers

a decreasing trendno p-value reported

In the longest observational study (over 4 years), the incidence of such complications showed a decreasing trend with long-term LCIG use [ 107 ].

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.